基质金属蛋白酶抑制剂类抗肿瘤药物临床研究进展

Advances in Clinical Research of Matrix Metalloproteinase Inhibitors as Anticancer Agents

基质金属蛋白酶是一类锌离子和钙离子依赖的蛋白水解酶,能够降解细胞外基质和基膜,在介导肿瘤血管新生、转移和侵袭等过程中发挥重要作用,基质金属蛋白酶抑制剂已成为当前抗肿瘤新药研发的热点之一。总结基质金属蛋白酶抑制剂用于抗肿瘤治疗的临床研究进展,为其进一步研究与应用提供参考。

Matrix metalloproteinases（MMPs） are a group of zinc and calcium dependent proteolytic enzymes that degrade extracellular matrix and basement membrane. They play very important roles in the processes of tumor angiogenesis, metastasis and invasion. MMP inhibitors（MMPIs） have become the focus of anticancer agents R＆D. This paper reviewed the progress in clinical development of MMPIs as anticancer agents, so as to provide references for their further investigation and application.